anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This Invention discloses new proteins & peptides & saccharides that haue anti cariogenic capabilities and that are characterized by the presence of one or more components that haue the ability to form a complex with calcium Ions: such as epsilon-polylysine that is conjugated with one or more bisphosphonyl- , biscarboxyl-, or 3-hydroxyphthalate-groups or conjugated with Casein phosphopeptide, phosvitin or with partially hydrolyzed phosvitin; such as partially hydrolyzed chitosan that is conjugated with one or more bisphosphonyl groups, Casein phosphopeptide or with phosvitin or partially hydrolyzed phosvitin; such as bisphosphonylated and biscarboxylated proteins with at least 40% of amino acids consisting of lysine and a molecular weight of above 2 kD (2000 dalton) and such as polymerized Casein phosphopeptide and partially hydrolyzed phosvitin. Especially basic polymers that are conjugated with bisphosphonyl-groups, such as bisphosphonylated epsilon-polylysine, are strong protectors due to the simultaneous presence in one molecule of strong calcium-complexing- and strong acid buffering components. In addition, polylysines, such as epsilon-polylysine haue demonstrated antibacterial activity against a large variety of oral cavity bacteria including acid producing bacteria. It indicates it's relevance for the protection of teeth in particular and for control of the bacterial flora in the oral cavity in general. The products can be used in formulations to protect teeth and to treat the oral cavity: toothpastes, gels, mouth rinses, artificial saliva's ....for patients and healthy consumers. They haue an attractive toxicological profile compared to fluoride, and can be used in food systems; they act additionally to the action of fluoride. The use in combination with fluoride provides excellent and enhanced protection at minimum fluoride dosage. The Invention encompasses competent protein & peptide & saccharide structures, based an in-vitro and in-vivo experiments.
<P>PROBLEM TO BE SOLVED: To repair the injury of microfibrils in a keratin fiber such as a hair damaged by dyeing, permanent wave treatment, or the like, and recover a hair flow having a favorable touch feeling without having undulation.  <P>SOLUTION: The keratin fiber microfibril injury-repairing agent contains 0.001-10 wt. % component containing carboxy and phenolic hydroxy groups in its molecule and 0.001-10 wt. % of 1 kind or ≥2 kinds of components selected from an amino acid, a protein hydrolysate and a keratin hydrolysate. The hair cosmetic contains the agent. The hair cosmetic can repair the injury of microfibrils in the damaged keratin fiber, and recover the favorable touch of the keratin fiber before getting the damage and the settled hair flow without having the undulation.  <P>COPYRIGHT: (C)2004,JPO
Systems, devices and methods for performing inventory management using RFID technology. The system includes a double-door box for receiving one or more items containing RFID tags. Items are scanned against a baseline content data to confirm all items are present and whether any items have expired. The box has security features to prevent unauthorized access to its contents and create an audit trail of access. Access to the box may be granted when two users present separate authorized RFID-enabled cards, wrist bands, or other items. Multiple locking features provide for additional security. A drop box mechanism on top of the housing allows for items to be deposited into the box without the same security protocols needed for accessing items. Scanning, authorization, and notification functions may be controlled remotely by an outside server or locally by a processing unit contained within the box itself.
FIELD: medicine. SUBSTANCE: prostaglandin E1 dinitroglycerol ester is an active substance of agent proposed. Proposed agent can be realized as hydrophilic polymeric gel containing prostaglandin E1 dinitroglycerol ester both at micellar and polymeric forms. Agent is applied on the surface of damaged skin as a thin layer both once and some times per a day depending on the pattern of pathological process. Agent causes the local vessel dilatation, decrease of platelet aggregation (that leads to the improved microcirculation), enhances regenerative processes at damaged site without expressed by-side effects on the systemic dynamics. Inclusion of indicated compound in the soft medicinal form, for example, gel allows to attain its high local concentration that is necessary for therapeutic effect attainment and to prevent its rapid biodegradation. EFFECT: enhanced effectiveness of agent.
The colon cleansing efficacy and safety of OsmoPrep was evaluated in 2 randomized, investigator-blinded, actively controlled, multicenter, U.S. trials in patients scheduled to have an elective colonoscopy. The trials consisted of a dose ranging and a confirmatory phase 3 study.

In the phase 3 trial, patients were randomized into one of the following three sodium phosphate treatment groups: 1) Visicol containing 60 grams of sodium phosphate given in split doses (30 grams in the evening before the colonoscopy and 30 grams on the next day) with at least 3.6 quarts of clear liquids; 2) OsmoPrep containing 60 grams of sodium phosphate given in split doses (30 grams in the evening before the colonoscopy and 30 grams on the next day) with 2.5 quarts of clear liquids; and 3) OsmoPrep containing 48 grams of sodium phosphate (30 grams in the evening before the colonoscopy and 18 grams on the next day) with 2 quarts of clear liquids. Patients were instructed to eat a light breakfast before noon on the day prior to the colonoscopy and then were told to drink only clear liquids after noon on the day prior to the colonoscopy.

The primary efficacy endpoint was the overall colon cleansing response rate in the 4-point Colonic Contents Scale. Response was defined as a rating of “excellent” or “good” on the 4-point scale as determined by the blinded colonoscopist. This phase 3 study was planned to assess the non-inferiority of the two OsmoPrep groups compared to the Visicol group.

The efficacy analysis included 704 adult patients who had an elective colonoscopy. Patients ranged in age from 21 to 89 years old (mean age 56 years old) with 55% female and 45% male patients. Race was distributed as follows: 87% Caucasian, 10% African American, and 3% other race. The OsmoPrep 60 gram and 48 gram treatment groups demonstrated non-inferiority compared to Visicol. See Table 1 for the results.

1 Colon-cleansing efficacy was based on response rate to treatment. A patient was considered to be a responder if overall colon cleansing was rated as “excellent” or “good” on a 4-point scale based on the amount of retained “colonic contents.” Excellent was defined as greater than 90% of mucosa seen, mostly liquid stool, minimal suctioning needed for adequate visualization. Good was defined as greater than 90% of mucosa seen, mostly liquid stool, significant suctioning needed for adequate visualization. Fair was defined as greater than 90% of mucosa seen, mixture of liquid and semisolid stool, could be suctioned and/or washed. Inadequate was defined as less than 90% of mucosa seen, mixture of semisolid and solid stool which could not be suctioned or washed.  
2 On the day of the colonoscopy, study medication was taken 3 to 5 hours before the start of the colonoscopy.  
  
the day of the colonoscopy, study medication was taken 3 to 5 hours before the start of the colonoscopy.
The following adverse reactions have been identified during post-approval use of olanzapine. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure.

Adverse reactions reported since market introduction that were temporally (but not necessarily causally) related to olanzapine therapy include the following: allergic reaction (e.g., anaphylactoid reaction, angioedema, pruritus or urticaria), cholestatic or mixed liver injury, diabetic coma, diabetic ketoacidosis, discontinuation reaction (diaphoresis, nausea or vomiting), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), hepatitis, jaundice, neutropenia, pancreatitis, priapism, rash, restless legs syndrome, rhabdomyolysis, stuttering 1and venous thromboembolic events (including pulmonary embolism and deep venous thrombosis). Random cholesterol levels of ≥240 mg/dL and random triglyceride levels of ≥1000 mg/dL have been reported. 

1Stuttering was only studied in oral formulations. 

To report SUSPECTED ADVERSE REACTIONS, contact AvKARE, Inc. at 1-855-361-3993; email drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
UNLABELLED: To evaluate the effectiveness of a novel protocol, adopted in our institution, as a quality improvement project for congenital diaphragmatic hernia (CDH). A maximal lung protection (MLP) protocol was implemented in 2019. This strategy included immediate use of high-frequency oscillatory ventilation (HFOV) after birth, during the stay at the Neonatal Intensive Care Unit (NICU), and during surgical repair. HFOV strategy included low distending pressures and higher frequencies (15 Hz) with subsequent lower tidal volumes. Surgical repair was performed early, within 24 h of birth, if possible. A retrospective study of all inborn neonates prenatally diagnosed with CDH and without major associated anomalies was performed at the NICU of Schneider Children's Medical Center of Israel between 2009 and 2022. Survival rates and pulmonary outcomes of neonates managed with MLP were compared to the historical standard care cohort. Thirty-three neonates were managed with the MLP protocol vs. 39 neonates that were not. Major adverse outcomes decreased including death rate from 46 to 18% (p = 0.012), extracorporeal membrane oxygenation from 39 to 0% (p < 0.001), and pneumothorax from 18 to 0% (p = 0.013).
CONCLUSION: MLP with early surgery significantly improved survival and additional adverse outcomes of neonates with CDH. Prospective randomized studies are necessary to confirm the findings of the current study.
WHAT IS KNOWN: • Ventilator-induced lung injury was reported as the main cause of mortality in neonates with congenital diaphragmatic hernia (CDH). • Conventional ventilation is recommended by the European CDH consortium as the first-line ventilation modality; timing of surgery is controversial.
WHAT IS NEW: • A maximal lung protection strategy based on 15-Hz high-frequency oscillatory ventilation with low distending pressures as initial modality and early surgery significantly reduced mortality and other outcomes.
A memory cue followed by playing the computer game "Tetris" on own smartphone. Options to engage in self-administered booster sessions after day 1.
PROBLEM TO BE SOLVED: To obtain pre-shaving paper powder capable of making excellent sliding of an electric shaver and improving shaving effect. SOLUTION: This pre-shaving paper powder is obtained by peelably attaching spherical powder having 1-50μm radius and 0.92 <= spheroidicity >= 1 on the surface of a substrate is an aerial density of 1-20g/m<2> . Preferably, the substrate has paper-like shape and is formed by using fibers such as Manila hemp or synthetic pulp as a pulp raw material. The spherical powder is formed by a well-known method, using a nylon, etc., having 1-5 Mohs' hardness and coating a mixture of a binder, a dispersant and water on the base plate. When shaving is performed by using an electric shaver, the spherical powder can be applied on the skin of a face and sebum is absorbed in the substrate by coating the powder on the skin of the face. And, use feeling can also be made good without inducing clogging of the electric shaver.
PURPOSE: A composition and a health functional food containing a Pharbitidis Semen extract are provided to suppress the growth of pancreatic cancer cells, and to treat pancreatic cancer. CONSTITUTION: A composition and a health functional food for treating pancreatic cancer contains a Pharbitidis Semen extract. The extract is an organic solvent extract which is prepared using an organic solvent at 50 deg. C. for 24 hours. The composition contains a pharmaceutically acceptable carrier or diluents. Pancreatic cancer is pancreatic ductal adenocarcinoma. [Reference numerals] (AA) Relative cellular viability
O6-BG: 120 mg/m\^2 IV over 1 hour on day 1 of each cycle BCNU: 40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
Radiation therapy results in radiation-induced vasculopathy, characterized by alterations in the vascular architecture stemming from radiation exposure. The exact molecular pathways and associated pathologies of this condition have yet to be comprehensively understood. This study aimed to identify specific markers' roles in cerebral vascular endothelial injury pathogenesis after radiosurgery and explore their unique expression patterns in diverse pathologies post-stereotactic radiosurgery. A retrospective cohort study was conducted to assess the expression profiles of endothelial markers via immunohistochemical analysis in 25 adult patients (13 males and 12 females) who had undergone neurosurgical resection for various central nervous system pathologies following stereotactic radiosurgery or radiotherapy from 2001 to 2015. Our findings revealed strong immunohistochemical expression of ICAM-1 and E-selectin across various disease states, while MMP-9, PAI-1, and eNOS exhibited moderate expression levels. In contrast, VCAM-1 and P-Selectin had the weakest expression across all groups. Notably, while individual markers showed significant variations in expression levels when comparing different diseases (P < .001), no substantial differences were found in the overall immunohistochemical expression patterns across the 5 distinct pathologies studied (P = .407, via 2-way ANOVA). Despite the varied long-term effects of radiotherapy on the vascular endothelium, a common thread of inflammation runs through the pathology of these conditions. The distinct patterns of marker expression identified in our study suggest that different markers play unique roles in the development of radiation-induced vasculopathy. These findings offer insights that could lead to the development of novel preventive strategies and treatments.
OBJECTIVE: Investigating the anatomical connections between cervical sympathetic ganglia and spinal ganglia in rabbits and assessing the role of Neuropeptide Y in the pathogenesis of cervical vertigo.
METHOD: Part 1: 32 adult healthy male New Zealand white rabbits (whose skin is very sensitive, so rabbits are generally used for stimulation experiments) were randomly divided into the upper cervical sympathetic ganglia (SCSG) stimulation group and the lower cervical sympathetic ganglia (ICSG) stimulation group, with 16 rabbits in each group. The two groups were divided into an experimental group and a control group, with 8 rabbits in each group. The cervical ganglia of each group of white rabbits were injected with 4% FluoroGold solution and observed under a section microscope. Part 2: Sixty New Zealand white rabbits were randomly divided into a blank control (n = 12), SCSG stimulation group (n = 12), SCSG sham surgery control (n = 12), ICSG stimulation group (n = 12), and ICSG sham surgery control group (n = 12). The SCSG group and ICSG group were subjected to electrical stimulation (i.e. 30.0Hz, 10.0V, 5-minute pulse width of 0.5 ms square wave pulse), and specimens were made. The expression of NPY was detected using immunohistochemical methods.
RESULT: Neuropeptide Y was weakly expressed in all cervical ganglia (C1-C8). Compared with the sham surgery group, the superior cervical sympathetic ganglion stimulation group showed an increase in Neuropeptide Y positive cells in C2, C3, C4, and C5, with C2 and C3 showing the most significant increase. The number of C6, C7, and C8 Neuropeptide Y positive cells in the 3 C、3D and 4B, lower cervical sympathetic ganglion stimulated groups was higher than in the sham sham-operated group, and C6 and C7 significantly increased. Neuropeptide Y is like immunoreactive neurons in the cervical spinal ganglia, and the immunoreactive products are small brown particles distributed in the cytoplasm after electrical stimulation of the cervical sympathetic ganglia. The Neuropeptide Y content in the corresponding segment of the cervical spinal ganglia is significantly increased compared to the control group (P < .05).
CONCLUSION: In New Zealand white rabbits, nerve fibers are interconnected between the cervical sympathetic ganglion and the cervical spinal ganglion, and this neural fiber connection has a certain segmental nature, providing experimental basis for the existence of the cervical spinal cord external nerve reflex arc and elucidating the pathogenesis of cervical vertigo in terms of neural anatomy. By using neuroelectrophysiological methods, it has been confirmed that electrical stimulation in the cervical spinal ganglia can reach the corresponding cervical sympathetic ganglia on the same side through a certain conduction pathway, providing experimental basis in neuroelectrophysiology for the existence of the cervical extraspinal nerve reflex arc and elucidating the pathogenesis of cervical vertigo. NPY may be involved in the pathogenesis of cervical vertigo, providing a theoretical basis for the clinical diagnosis of cervical vertigo.
This invention describes a novel strategy to produce phosphine-functionalized biomolecules (e.g. peptides or proteins) for potential use in the design and development of site-specific radiopharmaceuticals for diagnosis or therapy of specific cancers. Hydrophilic alkyl phosphines, in general, tend to be oxidatively unstable. Therefore, incorporation of such phosphine functionalities on peptide (and other biomolecule) backbones, without oxidizing the P III  centers, is difficult. In this context this discovery reports on a new technology by which phosphines, in the form of bifunctional chelating agents, can be directly incorporated on biomolecular backbones using manual synthetic or solid phase peptide synthesis methodologies. The superior ligating abilities of phosphine ligands, with various diagnostically (e.g. TC-99m) or therapeutically (e.g. Re186/188, Rh-105, Au-199) useful radiometals, coupled with the findings that the resulting complexes demonstrate high in vivo stability makes this approach useful in the development of radiolabeled biomolecules for applications in the design of tumor-specific radiopharmaceuticals.
Surgical resection remains the primary treatment modality for bone tumors. However, it is prone to local bone defects and tumor recurrence. Therefore, there is an urgent need for multifunctional biomaterials that combine tumor treatment and bone repair after bone tumor surgery. Herein, a chitosan composite scaffold (CS/DOX@Ti-MOF) was designed for both tumor therapy and bone repair. Among them, the amino-functionalized Ti-based metal-organic framework (NH2-MIL-125 (Ti), Ti-MOF) has a high specific surface area of 1116 m2/g and excellent biocompatibility, and promotes osteogenic differentiation. The doxorubicin (DOX) loading capacity of Ti-MOF was 322 ± 21 mg/g, and DOX@Ti-MOF has perfect antitumor activity. Furthermore, the incorporation of DOX@Ti-MOF improved the physical and mechanical properties of the composite scaffolds, making the scaffold surface rough and favorable for cells to attach. CS/DOX@Ti-MOF retains the unique properties of each component. It responds to the release of DOX in the tumor microenvironment to remove residual tumor cells, followed by providing a site for cell attachment, proliferation, and differentiation. This promotes bone repair and achieves the sequential treatment of postoperative bone tumors. Overall, CS/DOX@Ti-MOF may be a promising substitute for postoperative bone tumor clearance and bone defect repair. It also provides a possible strategy for postoperative bone tumor treatment.
PURPOSE:To obtain a bathing agent composition having improved physical properties of formulation and excellent feeling of skin in bathing by mixing silicon resin powder. CONSTITUTION:Silicon resin powder is mixed with usual bathing agent component in an amount of 0.01 to 20 pts.wt., preferably 0.05 to 5 pts.wt. to 100 pts.wt. of the total at normal temperature and uniformly stirred to afford the objective bathing agent composition. The silicon resin powder is a net-like polymer in which siloxane bonding is three-dimensionally extended and white resinous powder sold on the market, e.g., 'KMP-590(R)' produced by SHINETSU KAGAKU KOGYO K.K., is able to be used. By mixing silicon resin powder, fluidity of formulation is improved and weak point of dripping is able to be removed.
The invention discloses a new application of Sarcaboside B for preventing and treating osteoporosis. The osteoporosis is one of major diseases which harm human health, and osteoporosis patients are increasing with the aging of the population, thus enormous social, medical and economic burden is brought in the whole word. Although relevant experts and scholars at home and abroad attach great importance to the osteoporosis, effective medicines for treating the osteoporosis are scare. In-vivo tests prove that the Sarcaboside B has an obvious effect of resting the osteoporosis. Experimental results show that the Sarcaboside B can be used for inhibiting the increasing of the bone conversion rate caused by ovariectomy and the destruction of bones, meanwhile can be used for increasing the concentration of blood calcium and is beneficial to the deposition of bones. The Sarcaboside B has a therapeutical effect on the osteoporosis caused by the antiestrogen deficiency and has no estrogen-like side effect.
INTRODUCTION: Frailty is associated with adverse outcomes among patients attending emergency departments (EDs). While multiple frailty screens are available, little is known about which variables are important to incorporate and how best to facilitate accurate, yet prompt ED screening. To understand the core requirements of frailty screening in ED, we conducted an international, modified, electronic two-round Delphi consensus study.
METHODS: A two-round electronic Delphi involving 37 participants from 10 countries was undertaken. Statements were generated from a prior systematic review examining frailty screening instruments in ED (logistic, psychometric and clinimetric properties). Reflexive thematic analysis generated a list of 56 statements for Round 1 (August-September 2021). Four main themes identified were: (i) principles of frailty screening, (ii) practicalities and logistics, (iii) frailty domains and (iv) frailty risk factors.
RESULTS: In Round 1, 13/56 statements (23%) were accepted. Following feedback, 22 new statements were created and 35 were re-circulated in Round 2 (October 2021). Of these, 19 (54%) were finally accepted. It was agreed that ideal frailty screens should be short (<5 min), multidimensional and well-calibrated across the spectrum of frailty, reflecting baseline status 2-4 weeks before presentation. Screening should ideally be routine, prompt (<4 h after arrival) and completed at first contact in ED. Functional ability, mobility, cognition, medication use and social factors were identified as the most important variables to include.
CONCLUSIONS: Although a clear consensus was reached on important requirements of frailty screening in ED, and variables to include in an ideal screen, more research is required to operationalise screening in clinical practice.